Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.

"Conflict of interest statement: All authors are employees of Takeda Development Center Americas, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals America, Inc. Funding for this study was provided by Takeda Development Center Americas, Inc."

"Funding: The clinical studies were funded by Takeda Development Center Americas, Inc. Medical writing assistance was provided by inVentiv Medical Communications and was funded by Takeda Pharmaceuticals USA, Inc."

"The phase I, randomized, open-label, single-center, multiple-dose, two-period crossover study was conducted at Celerion in Tempe, AZ, from January to April 2014 [ClinicalTrials.gov identifier: NCT02064907]. Study protocols were developed according to the Food and Drug Administration Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products [], approved by the Independent Investigational Review Board, and conducted compliant with the Declaration of Helsinki and the International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP) [; ]."